LARIMAR THERAPEUTICS
6.9250
08-October-24 12:24:34
15 minutes delayed
Stocks
+0.4450
+6.87%
Today's range
6.4500 - 6.9535
ISIN
N/A
Source
NASDAQ
-
Larimar Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Days
28 Mar 2023 16:05:00 By Nasdaq GlobeNewswire
-
Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results
14 Mar 2023 07:00:01 By Nasdaq GlobeNewswire
-
Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer
07 Feb 2023 16:05:00 By Nasdaq GlobeNewswire
-
Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference
21 Nov 2022 16:05:00 By Nasdaq GlobeNewswire
-
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
10 Nov 2022 07:00:04 By Nasdaq GlobeNewswire
-
Larimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology Day
07 Nov 2022 16:05:01 By Nasdaq GlobeNewswire
-
20 Oct 2022 08:00:01 By Nasdaq GlobeNewswire
-
19 Oct 2022 16:05:00 By Nasdaq GlobeNewswire
-
16 Sep 2022 13:00:00 By Nasdaq GlobeNewswire
-
Larimar Therapeutics Announces $70 Million Underwritten Offering
14 Sep 2022 07:04:00 By Nasdaq GlobeNewswire
-
14 Sep 2022 07:01:00 By Nasdaq GlobeNewswire
-
28 Jul 2022 16:05:00 By Nasdaq GlobeNewswire
-
28 Jun 2022 08:00:02 By Nasdaq GlobeNewswire
-
Larimar Therapeutics Announces Upcoming Scientific Conference Presentations
02 Jun 2022 08:00:02 By Nasdaq GlobeNewswire
-
19 May 2022 08:00:01 By Nasdaq GlobeNewswire
-
Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results
12 May 2022 07:00:02 By Nasdaq GlobeNewswire
-
Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results
25 Mar 2022 07:00:00 By Nasdaq GlobeNewswire
-
Larimar Therapeutics Provides Update on CTI-1601 Clinical Program
14 Feb 2022 16:01:00 By Nasdaq GlobeNewswire